Characterization and LDL-C Management in a Cohort of High and Very High Cardiovascular Risk Patients: the PORTRAIT-DYS Study
Source : https://pubmed.ncbi.nlm.nih.gov/37933175/
We found that LDL-C control was very low in patients at higher risk of CV events. An alarming gap between guidelines on dyslipidemia management and clinical implementation persists, even in...
In this European study, poor LDL-C control was seen across all cohorts, with LDL-C goal attainment rates of 32%, 10%, and 18% for high-risk CV, ASCVD equivalent, and ASCVD cohorts, respectively.
Share
Cardiovascular Disease Prevention in Women – the Current State in 2023
Recent studies have demonstrated the need to account for risk factors specific to women in current risk assessment models for CVD, including early menarche, polycystic ovary syndrome, adverse pregnancy outcomes,...
At-risk women benefit similarly to lipid-lowering and other preventive therapies as men but are less likely to be treated.
Share
Site-Specific Genome Editing in Treatment of Inherited Diseases: Possibility, Progress, and Perspectives
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388762/
Advancements in genome editing enable permanent changes of DNA sequences in a site-specific manner, providing promising approaches for treating human genetic disorders caused by gene mutations.
Site-specific genome editing systems are exciting, inspiring, and promising. With continuous improvement of delivery vehicles, enzymes, and repair pathways in their accuracy, specificity, and efficiency, the scope of their applications in inherited diseases such as heterozygous familial hypercholesterolemia will expand.
Share
Low-Density Lipoprotein Cholesterol Reduction Therapies for Secondary Prevention in Patients With Stroke: a Network Meta-Analysis
Source : https://www.eurekaselect.com/article/135397
Patients with previous strokes are at a higher risk of stroke recurrence. Current guidelines recommend a range of low-density lipoprotein cholesterol (LDL-C)-lowering treatments to reduce the risk of recurrent stroke....
Overall, 9 trials comprising 17,226 patients were included. Treatment with statins was related to an increased risk of hemorrhagic stroke versus placebo (RR: 1.57, 95% CrI: 1.13-2.21).
Share
Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: a Retrospective Cohort Study Based on the AIFA Monitoring Registries
Source : https://pubmed.ncbi.nlm.nih.gov/37850449/
Background Information on the real-world use of proprotein convertase subtilisin kexin 9 inhibitors (PCKS9is) in familial hypercholesterolemia are limited.
A group of international researchers showed that the full achievement of European Atherosclerosis Society/European Society of Cardiology LDL‐C goals should require a lower threshold for PCSK9 inhibitor initiation and eventually combination of multiple lipid‐lowering therapies.
Share